PubMed:24671324 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"9821","span":{"begin":0,"end":21},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9822","span":{"begin":28,"end":38},"obj":"ChemicalEntity"},{"id":"9823","span":{"begin":43,"end":56},"obj":"ChemicalEntity"},{"id":"9824","span":{"begin":90,"end":97},"obj":"OrganismTaxon"},{"id":"9825","span":{"begin":101,"end":131},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9826","span":{"begin":133,"end":143},"obj":"ChemicalEntity"},{"id":"9827","span":{"begin":158,"end":171},"obj":"ChemicalEntity"},{"id":"9828","span":{"begin":249,"end":269},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9829","span":{"begin":273,"end":281},"obj":"OrganismTaxon"},{"id":"9830","span":{"begin":294,"end":306},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9831","span":{"begin":388,"end":396},"obj":"OrganismTaxon"},{"id":"9832","span":{"begin":432,"end":435},"obj":"OrganismTaxon"},{"id":"9833","span":{"begin":441,"end":471},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9834","span":{"begin":485,"end":506},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9835","span":{"begin":515,"end":526},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9836","span":{"begin":564,"end":574},"obj":"ChemicalEntity"},{"id":"9837","span":{"begin":586,"end":599},"obj":"ChemicalEntity"},{"id":"9838","span":{"begin":604,"end":613},"obj":"ChemicalEntity"},{"id":"9839","span":{"begin":756,"end":776},"obj":"DiseaseOrPhenotypicFeature"},{"id":"9840","span":{"begin":788,"end":798},"obj":"ChemicalEntity"},{"id":"9841","span":{"begin":814,"end":827},"obj":"ChemicalEntity"},{"id":"9842","span":{"begin":839,"end":847},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"9821","obj":"MESH:D019115"},{"id":"A2","pred":"db_id","subj":"9822","obj":"MESH:D000069286"},{"id":"A3","pred":"db_id","subj":"9823","obj":"MESH:D003907"},{"id":"A4","pred":"db_id","subj":"9824","obj":"NCBITaxon:9606"},{"id":"A5","pred":"db_id","subj":"9825","obj":"MESH:D008258"},{"id":"A6","pred":"db_id","subj":"9826","obj":"MESH:D000069286"},{"id":"A7","pred":"db_id","subj":"9827","obj":"MESH:D003907"},{"id":"A8","pred":"db_id","subj":"9828","obj":"MESH:D001424"},{"id":"A9","pred":"db_id","subj":"9829","obj":"NCBITaxon:9606"},{"id":"A10","pred":"db_id","subj":"9830","obj":"MESH:D009369"},{"id":"A11","pred":"db_id","subj":"9831","obj":"NCBITaxon:9606"},{"id":"A12","pred":"db_id","subj":"9832","obj":"NCBITaxon:9606"},{"id":"A13","pred":"db_id","subj":"9833","obj":"MESH:D008258"},{"id":"A14","pred":"db_id","subj":"9834","obj":"MESH:D019115"},{"id":"A15","pred":"db_id","subj":"9835","obj":"MESH:D009503"},{"id":"A16","pred":"db_id","subj":"9836","obj":"MESH:D000069286"},{"id":"A17","pred":"db_id","subj":"9837","obj":"MESH:D003907"},{"id":"A18","pred":"db_id","subj":"9838","obj":"MESH:D000069283"},{"id":"A19","pred":"db_id","subj":"9839","obj":"MESH:D001424"},{"id":"A20","pred":"db_id","subj":"9840","obj":"MESH:D000069286"},{"id":"A21","pred":"db_id","subj":"9841","obj":"MESH:D003907"},{"id":"A22","pred":"db_id","subj":"9842","obj":"NCBITaxon:9606"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T1","span":{"begin":432,"end":435},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"NCBItxid:9606"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"T2","span":{"begin":133,"end":307},"obj":"Sentence"},{"id":"T3","span":{"begin":308,"end":397},"obj":"Sentence"},{"id":"T4","span":{"begin":398,"end":614},"obj":"Sentence"},{"id":"T5","span":{"begin":615,"end":702},"obj":"Sentence"},{"id":"T6","span":{"begin":703,"end":905},"obj":"Sentence"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":12,"end":21},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":497,"end":506},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":515,"end":526},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0004830"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0004830"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0001475"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":148,"end":152},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":223,"end":232},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":289,"end":293},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":332,"end":339},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":410,"end":414},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":423,"end":427},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":576,"end":580},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":804,"end":808},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":869,"end":873},"obj":"GeneOrGeneProduct"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":148,"end":152},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":289,"end":293},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":332,"end":339},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":576,"end":580},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":804,"end":808},"obj":"GeneOrGeneProduct"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":12,"end":21},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":101,"end":131},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":249,"end":269},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":294,"end":306},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":441,"end":471},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":497,"end":506},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":515,"end":526},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":756,"end":776},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"originalLabel","subj":"T1","obj":"D005208"},{"id":"A7","pred":"originalLabel","subj":"T7","obj":"D009503"},{"id":"A2","pred":"originalLabel","subj":"T2","obj":"D008258"},{"id":"A4","pred":"originalLabel","subj":"T4","obj":"D009369"},{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D001424"},{"id":"A6","pred":"originalLabel","subj":"T6","obj":"D005208"},{"id":"A5","pred":"originalLabel","subj":"T5","obj":"D008258"},{"id":"A8","pred":"originalLabel","subj":"T8","obj":"D001424"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":12,"end":21},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":101,"end":131},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":249,"end":272},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":441,"end":471},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":497,"end":506},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":515,"end":526},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":668,"end":670},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":756,"end":776},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0001475"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0005113"},{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0004830"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0100280"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0004830"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005113"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0017319"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0100280"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":12,"end":21},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":101,"end":131},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":249,"end":269},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":294,"end":306},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":441,"end":471},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":497,"end":506},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":515,"end":526},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":756,"end":776},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"ID:","subj":"T4","obj":"D009369"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D009503"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D008258"},{"id":"A8","pred":"ID:","subj":"T8","obj":"D001424"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D001424"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D005208"},{"id":"A2","pred":"ID:","subj":"T2","obj":"D008258"},{"id":"A6","pred":"ID:","subj":"T6","obj":"D005208"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":12,"end":21},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":101,"end":131},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":249,"end":269},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":294,"end":306},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":441,"end":471},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":497,"end":506},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":515,"end":526},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":756,"end":776},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"#label","subj":"T4","obj":"D009369"},{"id":"A1","pred":"#label","subj":"T1","obj":"D005208"},{"id":"A3","pred":"#label","subj":"T3","obj":"D001424"},{"id":"A8","pred":"#label","subj":"T8","obj":"D001424"},{"id":"A6","pred":"#label","subj":"T6","obj":"D005208"},{"id":"A2","pred":"#label","subj":"T2","obj":"D008258"},{"id":"A5","pred":"#label","subj":"T5","obj":"D008258"},{"id":"A7","pred":"#label","subj":"T7","obj":"D009503"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T1","span":{"begin":28,"end":38},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":43,"end":56},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":133,"end":143},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":158,"end":171},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":564,"end":574},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":586,"end":599},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":604,"end":613},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":788,"end":798},"obj":"ChemicalEntity"},{"id":"T16","span":{"begin":814,"end":827},"obj":"ChemicalEntity"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"D000069286"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_52717"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D003907"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D000069286"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_52717"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D003907"},{"id":"A8","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D000069286"},{"id":"A10","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_52717"},{"id":"A11","pred":"ID:","subj":"T11","obj":"D003907"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A13","pred":"ID:","subj":"T13","obj":"ChemicalEntity"},{"id":"A14","pred":"ID:","subj":"T14","obj":"D000069286"},{"id":"A15","pred":"ID:","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_52717"},{"id":"A16","pred":"ID:","subj":"T16","obj":"D003907"},{"id":"A17","pred":"ID:","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":90,"end":97},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":273,"end":281},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":388,"end":396},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":432,"end":435},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":839,"end":847},"obj":"OrganismTaxon"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T16","span":{"begin":814,"end":827},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":788,"end":798},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":604,"end":613},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":586,"end":599},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":564,"end":574},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":158,"end":171},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":133,"end":143},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":43,"end":56},"obj":"ChemicalEntity"},{"id":"T1","span":{"begin":28,"end":38},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":756,"end":776},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T62215","span":{"begin":515,"end":526},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":497,"end":506},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T45991","span":{"begin":441,"end":471},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":294,"end":306},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T99350","span":{"begin":249,"end":269},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":101,"end":131},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T40593","span":{"begin":12,"end":21},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T28207","span":{"begin":839,"end":847},"obj":"OrganismTaxon"},{"id":"T81211","span":{"begin":432,"end":435},"obj":"OrganismTaxon"},{"id":"T67989","span":{"begin":388,"end":396},"obj":"OrganismTaxon"},{"id":"T2012","span":{"begin":273,"end":281},"obj":"OrganismTaxon"},{"id":"T34751","span":{"begin":90,"end":97},"obj":"OrganismTaxon"}],"attributes":[{"id":"A17","pred":"ID:","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A16","pred":"ID:","subj":"T16","obj":"D003907"},{"id":"A15","pred":"ID:","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_52717"},{"id":"A14","pred":"ID:","subj":"T14","obj":"D000069286"},{"id":"A13","pred":"ID:","subj":"T13","obj":"ChemicalEntity"},{"id":"A12","pred":"ID:","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A11","pred":"ID:","subj":"T11","obj":"D003907"},{"id":"A10","pred":"ID:","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_52717"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D000069286"},{"id":"A8","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D003907"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_52717"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D000069286"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D003907"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_52717"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D000069286"},{"id":"A20797","pred":"#label","subj":"T8","obj":"D001424"},{"id":"A7460","pred":"#label","subj":"T62215","obj":"D009503"},{"id":"A35700","pred":"#label","subj":"T6","obj":"D005208"},{"id":"A44207","pred":"#label","subj":"T45991","obj":"D008258"},{"id":"A90710","pred":"#label","subj":"T4","obj":"D009369"},{"id":"A61237","pred":"#label","subj":"T99350","obj":"D001424"},{"id":"A1901","pred":"#label","subj":"T2","obj":"D008258"},{"id":"A97494","pred":"#label","subj":"T40593","obj":"D005208"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":497,"end":506},"obj":"HP_0100537"},{"id":"T2","span":{"begin":515,"end":526},"obj":"HP_0001875"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}

{"project":"PubCasesHPO","denotations":[{"id":"TI1","span":{"begin":12,"end":21},"obj":"HP:0100537"},{"id":"AB1","span":{"begin":497,"end":506},"obj":"HP:0100537"},{"id":"AB2","span":{"begin":515,"end":526},"obj":"HP:0001875"}],"text":"Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.\nBortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies. However, information is limited concerning the safety of the regimen in elderly patients. We report a case of a 76-year-old man with Waldenström macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab. Despite immediate intravenous antimicrobial therapy, he succumbed 23 h after the onset. Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."}